Department of Medicine, Växjö County Hospital, Växjö, Sweden.
Department of Anaesthesia and Intensive Care, Lund University and Skane University Hospital, Lund, S-22185 Sweden.
Perioper Med (Lond). 2015 Sep 29;4:9. doi: 10.1186/s13741-015-0019-7. eCollection 2015.
The European Medicines Agency does not recommend the use of hydroxyethyl starch-based volume replacement solutions in critically ill patients due to an increased risk of renal failure. However, this recommendation is questionable for its perioperative use. Several recent randomised controlled studies do not indicate a risk for renal failure-not even after high-risk surgery. Human albumin is used in our neurointensive care unit as a part of the "Lund concept" of brain injury resuscitation, and albumin has been introduced in elective neurosurgery instead of starch. The aim of our prospective unblinded observational cohort study was to compare the degree of dilutive coagulopathy after albumin and starch intra-operative fluid therapy.
Thirty-nine patients undergoing elective brain tumour surgery with craniotomy received either 130/0.42 hydroxyethyl starch or 5 % albumin infusions. The first 18 patients received starch, whereas the rest received albumin. Rotational thromboelastometry with ROTEM and platelet aggregometry with Multiplate were performed before surgery, after the first and second consecutive colloid infusions (250/500 ml albumin or 500/1000 ml starch) and at the end of surgery.
Both intra- and inter-group comparisons showed more deranged ROTEM parameters after the higher doses of starch. Multiplate detected changes only in the albumin group after 500-ml infusion. Blood los did not differ between groups, nor did haemoglobin preoperatively or at end of surgery. Lower volumes of albumin were required to maintain stable intra-operative haemodynamic parameters; 250/500 ml albumin corresponded to 500/1000 ml starch.
Hydroxyethyl starch affected coagulation at lower volumes, with a more prominent effect on clot structure at the end of surgery, corroborating previous research. Only albumin decreased platelet aggregation, and 5 % albumin had a more potential volume effect than 130/0.42 hydroxyethyl starch.
由于肾衰竭风险增加,欧洲药品管理局不建议在危重症患者中使用基于羟乙基淀粉的容量替代溶液。然而,这种建议在围手术期使用时是值得商榷的。最近的几项随机对照研究并未表明存在肾衰竭风险——即使是高危手术后也没有。人血白蛋白在我们的神经重症监护病房中作为脑损伤复苏“Lund 概念”的一部分使用,并且在择期神经外科手术中用人血白蛋白代替淀粉。我们前瞻性、非盲、观察性队列研究的目的是比较术中白蛋白和淀粉液体治疗后稀释性凝血功能障碍的程度。
39 例接受开颅手术的择期脑肿瘤患者接受了 130/0.42 羟乙基淀粉或 5%人血白蛋白输注。前 18 例患者接受淀粉治疗,其余患者接受白蛋白治疗。在手术前、第一次和第二次连续胶体输注(250/500ml 白蛋白或 500/1000ml 淀粉)后以及手术结束时进行旋转血栓弹性测定(ROTEM)和血小板聚集测定(Multiplate)。
淀粉高剂量组的 ROTEM 参数变化更明显,无论是组内还是组间比较。输注 500ml 后,Multiplate 仅在白蛋白组中检测到变化。两组间的失血量无差异,术前和手术结束时的血红蛋白也无差异。需要更少的白蛋白体积来维持术中血流动力学参数的稳定;250/500ml 白蛋白相当于 500/1000ml 淀粉。
羟乙基淀粉在较低剂量时影响凝血,在手术结束时对凝块结构的影响更为明显,这与之前的研究结果一致。只有白蛋白降低了血小板聚集,而 5%人血白蛋白的容量效应比 130/0.42 羟乙基淀粉更强。